France : FDA OKs Sanofi allergy drug for younger children.Byline: pinto03 French drug maker Sanofi-Aventis SA and Belgian biotech drug maker UCB UCB - University of California at Berkeley said Monday their once-daily allergy medication Xyzal has received expanded U.S. approval for children as young as six months. The FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. has approved the drug to treat indoor allergies and hives hives (urticaria), rash consisting of blotches or localized swellings (wheals) of the skin, caused by an allergic reaction (see allergy). The swelling is caused by distention of the skin capillaries and escape of serum and white cells into the skin and tissues. in children six months and older. The agency also cleared the drug for outdoor allergies in children older than two. Previously the drug, which is available in pill and liquid form, was approved to treat indoor and outdoor nasal allergies in children ages six and up. Company studies show that Xyzal significantly reduces sneezing To verbally tell somebody about a new and interesting Web site. See viral marketing. , itchy nose, runny nose runny nose Vox populi → medtalk Rhinorrhea , and itchy eyes for hay fever, along with itching and the size of hive outbreaks. Sanofi and UCB co-market Xyzal in the U.S. Shares of Sanofi-Aventis rose 6 cents Monday to close at $33.94. Copyright : Euclid Infotech Pvt. Ltd. Provided by Syndigate.info an Albawaba.com company |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion